These results suggest that HLA-A*02 reduces the risk of HAM/TSP, probably due to the reduction of HTLV-1 PVL by HLA-A*02-restricted Tax 11–19-specific CTLs. This evidence concerns the gene CNTN2 and tropical spastic paraparesis.